<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04466475</url>
  </required_header>
  <id_info>
    <org_study_id>RG1006317</org_study_id>
    <secondary_id>NCI-2019-06979</secondary_id>
    <secondary_id>10306</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>R01CA205248</secondary_id>
    <nct_id>NCT04466475</nct_id>
  </id_info>
  <brief_title>Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma</brief_title>
  <official_title>A Phase I Trial Evaluating Escalating Doses of 211At-Labeled Anti-CD38 Monoclonal Antibody (211At-OKT10-B10) Combined With Melphalan as Conditioning Prior to Autologous Hematopoietic Cell Transplantation for Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of 211At-OKT10-B10 when given&#xD;
      together with melphalan before a stem cell transplantation in treating patients with multiple&#xD;
      myeloma. The radioimmunotherapy drug 211At-OKT10-B10 is a monoclonal antibody, called&#xD;
      OKT10-B10, linked to a radioactive substance called 211At. OKT10-B10 attaches to CD38&#xD;
      positive cancer cells in a targeted way and delivers 211At to kill them. Drugs used in&#xD;
      chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells,&#xD;
      either by killing the cells, by stopping them from dividing, or by stopping them from&#xD;
      spreading. Giving 211At-OKT10-B10 with melphalan before a stem cell transplant may kill more&#xD;
      cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a dose-escalation study of 211At-OKT10-B10.&#xD;
&#xD;
      Patients receive 211At-OKT10-B10 intravenously (IV) continuously on days -7 to -4 and&#xD;
      melphalan via infusion on day -2. Patients then undergo peripheral blood stem cell (PBSC)&#xD;
      transplantation on day 0.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 30 days, between 80 and 90&#xD;
      days, at 6, 9, 12, 18, and 24 months, and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">March 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>Up to 30 days post-transplant</time_frame>
    <description>Defined a true dose limiting toxicity (DLT) probability of 25% of subjects, where a DLT is defined as any grade 3-5 nonhematologic regimen-related toxicity within the first 30 days following autologous hematopoietic cell transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of response</measure>
    <time_frame>Between days +80 to +90 post-transplant</time_frame>
    <description>Measured per the International Myeloma Working Group criteria. The response rates (partial response [PR] or better) will be estimated along with the exact 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>From response (PR or better) to disease relapse or death, assessed up to 5 years</time_frame>
    <description>Duration of response will be estimated using Kaplan-Meier methodology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From transplantation to death, assessed up to 2 years post-transplant</time_frame>
    <description>Kaplan-Meier methodology will be used to estimate the 2-year overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From transplantation to disease relapse or death, assessed up to 2 years post-transplant</time_frame>
    <description>Kaplan-Meier methodology will be used to estimate the 2-year progression-free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of minimal residual disease (MRD)</measure>
    <time_frame>At days 28, and +80 to +90 post-transplant</time_frame>
    <description>MRD will be assessed using multi-color flow cytometry and next generation sequencing in conjunction with functional imaging (i.e., positron emission tomography-computed tomography). The proportion who achieve MRD will be estimated along with an exact 95% confidence interval.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment (211At-OKT10-B10, melphalan, PBSC transplantation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 211At-OKT10-B10 IV continuously on days -7 to -4 and melphalan via infusion on day -2. Patients then undergo PBSC transplantation on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (211At-OKT10-B10, melphalan, PBSC transplantation)</arm_group_label>
    <other_name>211At-OKT10-B10</other_name>
    <other_name>[211At]OKT10-B10</other_name>
    <other_name>Astatine 211-labeled Anti-CD38 Monoclonal Antibody OKT10-B10</other_name>
    <other_name>Astatine At 211 Anti-CD38 MoAb OKT10-B10</other_name>
    <other_name>Astatine-211-OKT10-B10</other_name>
    <other_name>At211-OKT10-B10</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given via infusion</description>
    <arm_group_label>Treatment (211At-OKT10-B10, melphalan, PBSC transplantation)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Nitrogen Mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo PBSC transplantation</description>
    <arm_group_label>Treatment (211At-OKT10-B10, melphalan, PBSC transplantation)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of multiple myeloma&#xD;
&#xD;
          -  Patients must have autologous hematopoietic stem cells collected with a minimum CD34+&#xD;
             stem cell yield of &gt;= 4 x 10^6 CD34+ cells/kg of body weight&#xD;
&#xD;
          -  Subjects must have disease meeting criteria for clinical relapse or progressive&#xD;
             disease (International Myeloma Working Group [IMWG] consensus criteria) and a history&#xD;
             of &gt;= 1 prior autologous stem cell transplant(s)&#xD;
&#xD;
          -  Subjects must have received at least 3 prior lines of therapy: an immunomodulatory&#xD;
             drug, a proteasome inhibitor, and a CD38-targeting antibody&#xD;
&#xD;
             * Aline of therapy is defined as one or more cycles of a planned treatment program.&#xD;
             This may consist of one or more planned cycles of a single-agent therapy or&#xD;
             combination therapy, as well as a sequence of treatments administered in a planned&#xD;
             manner. For example, a planned treatment approach of induction therapy followed by&#xD;
             autologous stem cell transplantation, followed by maintenance is considered one line&#xD;
             of therapy. A new line of therapy starts when a planned course of therapy is modified&#xD;
             to include other treatment agents (alone or in combination) as a results of disease&#xD;
             progression, relapse, or toxicity. A new line of therapy also starts when a planned&#xD;
             period of observation off therapy is interrupted by a need for additional treatment&#xD;
             for the disease&#xD;
&#xD;
          -  Subjects must have an estimated creatinine clearance greater than 60 ml per minute by&#xD;
             the following formula (Cockcroft-Gault). Serum creatinine value must be within 28 +/-&#xD;
             days prior to registration&#xD;
&#xD;
          -  Subjects must have an Eastern Cooperative Oncology Group (ECOG) score =&lt; 2 or&#xD;
             Karnofsky score &gt;= 70%&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a history of plasma cell leukemia&#xD;
&#xD;
          -  History of central nervous system involvement by multiple myeloma&#xD;
&#xD;
          -  Prior radioimmunotherapy or radiation of &gt; 20 Gy to pelvis or at maximally tolerated&#xD;
             levels to any critical normal organ&#xD;
&#xD;
          -  Prior allogeneic hematopoietic cell transplant&#xD;
&#xD;
          -  More than 2 prior autologous hematopoietic cell transplants&#xD;
&#xD;
          -  Subjects with medullary or extramedullary plasmacytoma/s measuring &gt; 3 cm by magnetic&#xD;
             resonance imaging (MRI) or positron emission tomography (PET)-computed tomography (CT)&#xD;
             (radiated lesions are exempt from this criterion)&#xD;
&#xD;
          -  Subjects with a history of any one of the following cardiovascular conditions within&#xD;
             the past 6 months: Class III or IV heart failure as defined by the New York Heart&#xD;
             Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable&#xD;
             angina, or other clinically significant cardiac disease as determined by the principal&#xD;
             investigator (PI) or designee&#xD;
&#xD;
          -  Subjects with corrected QT (QTc) prolongation at baseline&#xD;
&#xD;
          -  Subjects with a history of cardiac arrhythmia and a heart rate &gt; 100 beats per minute&#xD;
             (BPM) (oral beta-blocker [excluding sotalol] and/or calcium channel blocker therapy&#xD;
             are acceptable to achieve rate control)&#xD;
&#xD;
          -  History of reactive airway disease and clinically significant asthma requiring any&#xD;
             form of medical treatment in the prior three months&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 40%&#xD;
&#xD;
          -  Corrected diffusing capacity of the lungs for carbon monoxide (DLCO) &lt; 50% or&#xD;
             receiving supplemental continuous oxygen&#xD;
&#xD;
          -  Liver abnormalities: fulminant liver failure, cirrhosis of the liver with evidence of&#xD;
             portal hypertension, alcoholic hepatitis, esophageal varices, hepatic encephalopathy,&#xD;
             uncorrectable hepatic synthetic dysfunction as evidenced by prolongation of the&#xD;
             prothrombin time, ascites related to portal hypertension, bacterial or fungal liver&#xD;
             abscess, biliary obstruction, chronic viral hepatitis, or symptomatic biliary disease.&#xD;
&#xD;
          -  Bilirubin &gt; 2 times the upper limit of normal&#xD;
&#xD;
          -  Aspartate aminotransferase [AST] and alanine aminotransferase [ALT] &gt; 2 times the&#xD;
             upper limit of normal&#xD;
&#xD;
          -  Subjects who are known to be seropositive for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Women of childbearing potential who are pregnant (beta-human chorionic gonadotropin&#xD;
             [HCG]+) or breast feeding&#xD;
&#xD;
          -  Fertile men and women unwilling to use contraceptives during and for 12 months&#xD;
             post-transplant&#xD;
&#xD;
          -  Subjects with untreated and uncontrolled infection at time of enrollment&#xD;
&#xD;
          -  Subjects with known amyloid light-chain (AL) subtype amyloidosis&#xD;
&#xD;
          -  Known allergy to murine-based monoclonal antibodies&#xD;
&#xD;
          -  Known contraindications to radiotherapy&#xD;
&#xD;
          -  History of another primary malignancy that has not been in remission for at least 2&#xD;
             years (the following are exempt from the 2-year limit: non-melanoma skin cancer,&#xD;
             curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy&#xD;
             or a squamous intraepithelial lesion on Papanicolaou [PAP] smear)&#xD;
&#xD;
          -  Any anti-CD38 monoclonal antibody within 30 days of anticipated date of infusion of&#xD;
             211At-OKT10-B10&#xD;
&#xD;
          -  Individuals with a history of CTCAE grade 4 gastrointestinal toxicity associated with&#xD;
             prior high-dose melphalan conditioning therapy (previous autologous stem cell&#xD;
             transplant)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damian J. Green</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Damian J. Green</last_name>
    <phone>206-667-5398</phone>
    <email>dgreen@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Damian J. Green</last_name>
      <phone>206-667-5398</phone>
      <email>dgreen@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Damian J. Green</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

